Brivaracetam Application Scope

Brivaracetam is indicated for the treatment of partial-onset seizures in patients aged 1 month and older. It can be used as monotherapy or as adjunctive therapy in combination with other antiepileptic drugs.

Brivaracetam Characteristics

Ingredients:
- Brivaracetam

Properties: (Mechanism of Action) Brivaracetam binds with high affinity to synaptic vesicle protein 2A (SV2A), modulating neurotransmitter release and reducing seizure activity
Packaging Specification:
- Tablets: 60-count bottles
- Oral Solution: 300 mL bottles
- Injection: Single-use vials
Storage:
- General: Store at room temperature (15°C to 30°C / 59°F to 86°F)
- Oral Solution: Discard any unused portion 5 months after opening
Expiry Date: Refer to the packaging for specific expiration information.
Executive Standard: Refer to the prescribing information for detailed standards.
Approval Number: Refer to the official prescribing information for regulatory approval details.
Date of Revision: May 2023
Manufacturer: UCB, Inc.

Guidelines for the Use of Brivaracetam

Dosage and Administration:
- Adults (≥16 years):
  - Initial Dose: 50 mg twice daily
  - Maintenance Dose: Adjust between 25 mg to 100 mg twice daily based on response
  - Maximum Dose: 200 mg/day
- Pediatric Patients (1 month to <16 years):
  - Dosing: Based on body weight; administered twice daily
- Hepatic Impairment:
  - Adjustment: Recommended for all stages; reduce starting dose and do not exceed 150 mg/day
- Administration:
  - Oral: Tablets should be swallowed whole with liquid; do not chew or crush.
  - IV Injection: Administer over 2 to 15 minutes when oral administration is not feasible
Adverse Reactions:

Common Side Effects:
- Somnolence/sedation
- Dizziness
- Fatigue
- Nausea and vomiting
Contraindications: Hypersensitivity to brivaracetam or any of its inactive ingredients
Precautions:
- Suicidal Behavior and Ideation: Monitor patients for emerging or worsening depression, suicidal thoughts, or behavior.
- Neurological Effects: Caution with activities requiring mental alertness (e.g., driving) until drug effects are known.
- Psychiatric Effects: Monitor for behavioral changes, including irritability and aggression.
- Hypersensitivity Reactions: Discontinue if bronchospasm or angioedema occurs.
- Withdrawal: Gradual discontinuation is recommended to minimize the risk of increased seizure frequency

Interactions

Drug Interactions:
- Rifampin: May decrease brivaracetam levels; dosage adjustment recommended.
- Carbamazepine: May increase carbamazepine metabolite levels; monitor for toxicity.
- Phenytoin: May increase phenytoin levels; monitor concentrations.
- Levetiracetam: No added benefit when co-administered; consider monotherapy

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.